Key result
Recombinant human CTRP-1 prevented collagen-induced platelet aggregation in vitro and in vivo platelet thrombosis in nonhuman primates without altering bleeding times.
Why the study?
Does CTRP-1 prevent platelet thrombosis in preclinical models?
Does CTRP-1 prevent platelet thrombosis in preclinical models?
CTRP-1 demonstrates promising antiplatelet activity by blocking VWF binding to collagen, preventing thrombosis without increasing bleeding risk in preclinical models.
Answers are grounded in this paper and cite their sources.
CTRP-1 merits human translation studies; leaves open efficacy and safety in patients.
CTRP-1 is a novel member of the C1qTNF-related protein family containing family characteristic collagen and TNF-like domains and shows marked expression in vascular wall tissue. We observed that recombinant human CTRP-1 specifically bound to fibrillar collagen and blocked collagen-induced platelet aggregation. CTRP-1 completely or partially prevented VWF and GPVI-Fc4 binding to collagen, respectively. However, GPVI-Fc4 failed to compete for the binding of CTRP-1 to collagen. CTRP-1 had no effects on alpha(2)beta(1) integrin I-domain binding to collagen. Using whole human blood under flow at low and high shear rates, CTRP-1 prevented platelets from accumulating on a collagen-coated surface but had no effects on "platelet-rolling" on a surface coated with VWF. These data suggest that CTRP-1 prevents collagen-induced platelet aggregation by specific blockade of VWF binding to collagen. By using the Folts vascular injury model in nonhuman primates (Macaca fascicularis), we were able to demonstrate that CTRP-1 can prevent platelet thrombosis in vivo. This effect was achieved in the absence of changes in activated-clotting time (ACT) and template cut bleeding times, suggesting that CTRP-1 has promising antiplatelet thrombotic activity and most likely acts by pacifying the thrombogenic site of vascular injury.
No takes yet. Share an insight, caveat, or question.
Lasser et al. (2005) studied Platelet thrombosis. Recombinant human CTRP-1 was evaluated on Platelet aggregation and thrombosis. Recombinant human CTRP-1 prevented collagen-induced platelet aggregation in vitro and in vivo platelet thrombosis in nonhuman primates without altering bleeding times.
Synapse has enriched 10 related papers. Consider them for comparative context: